Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling
Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling
复制标题
DOI：
10.1046/j.1365-2141.2003.04676.x
复制
发表时间：
2003-11-01
影响因子：
6.5
通讯作者：
Riddell, SR
中科院分区：
文献类型：
--
作者：
Akatsuka, Y;Warren, EH;Riddell, SR
我们最近发现了一种新的次要组织相容性抗原，称为HA-8，它由人类白细胞抗原（HLA）-A * 0201或HLA-A * 0202呈递，并在组织中广泛表达。对577例HLA-A * 0201或A * 0202的白人患者进行回顾性分析，这些患者接受了来自人类白细胞抗原（HLA）相同同胞的造血干细胞移植，以确定HA-8差异是否与临床结局相关。在72名受者中检测到HA-8差异，46名（64%）患者发生了II-IV级移植物抗宿主病（GVHD），而503名无HA-8差异的患者中有251名（50%）。在调整急性GVHD的已知危险因素后，这种差异具有统计学意义（比值比，1.8; 95%置信区间，1.0 - 3.1; P = 0.04）。然而，两组之间的临床广泛慢性GVHD、总死亡率和复发性恶性肿瘤的危害没有统计学显著差异。这些数据表明，与受体HA-8差异相关的急性GVHD风险增加不足以改变其他临床结局。
We recently identified a new minor histocompatibility antigen, termed HA-8, which is presented by human leucocyte antigen (HLA)-A*0201 or HLA-A*0202 and expressed ubiquitously among tissues. A retrospective analysis of 577 Caucasian patients with HLA-A*0201 or A*0202 who had received a haematopoietic stem cell transplant from a human leucocyte antigen (HLA)-identical sibling was conducted to determine whether HA-8 disparity correlated with clinical outcome. HA-8 disparity was detected in 72 recipients, and grades II-IV graft-versus-host disease (GVHD) occurred in 46 (64%), compared with 251 (50%) of the 503 patients without HA-8 disparity. After adjusting for known risk factors for acute GVHD, this difference was statistically significant (odds ratio, 1.8; 95% confidence interval, 1.0-3.1; P = 0.04). However, the hazards of clinical extensive chronic GVHD, overall mortality and recurrent malignancy were not statistically significantly different between the two groups. These data suggest that the increased risk of acute GVHD associated with recipient HA-8 disparity was not sufficient to change other clinical outcomes.